UPDATE 1-'Moderate' evidence backs Dendreon vaccine-US CMS
November 10, 2010 at 17:55 PM EST
NEW YORK, Nov 10 (Reuters) - All of the available data for Dendreon Corp's controversial Provenge prostate cancer vaccine shows 'moderate' support for its use, according to a government analysis by the nation's Medicare Agency.